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The Added Value of Molecular Testing in Small Pancreatic Cysts
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Adam D. Toll1, Marluce Bibbo MD1
Background
Cystic lesions of the pancreas (CLP) represent a 
relatively common pathologic entity affecting at 
least 1% of medical patients and represent a 
spectrum of lesions from inflammatory 
pseudocysts to malignant neoplasms.(1,2) A 
significant percentage of these cysts are found 
incidentally during imaging work-up for unrelated 
conditions and require appropriate diagnostic 
testing to characterize the nature of the CLP. A 
multi-disciplinary approach to characterize CLP is 
currently used involving cytology, imaging, and 
cyst fluid analysis.  The most recent international 
guidelines recommend resection of pancreatic 
mucinous cysts >3 cm, or smaller cysts with 
positive cytology, mural nodules, or symptoms.(2) 
Recent work utilized DNA analysis to characterize 
CLP as either mucinous or serous, and assess 
malignant potential.(3,4) Focusing on k-ras gene 
point mutation, this group was able to detect 
mucinous differentiation (specificity 96%). 
Further, high amplitude k-ras mutations combined 
with allelic loss were 96% specific for malignancy. 
Correlation of k-ras mutation / allelic imbalances 
with CEA, however, showed poor agreement in the 
diagnosis of mucinous CLP. 
Our aim is to determine the added benefit of 
molecular testing in diagnosing small (≤3 cm) 
pancreatic cysts.
Methods Results Conclusion
63 pancreatic cysts ≤3 cm with fine-needle 
aspiration cytology, cyst fluid CEA levels, and 
molecular analysis (PathFinder TG; RedPath
Integrated Pathology, Pittsburgh PA) were 
retrospectively obtained. The final study group was 
60% male and 40% female. The average age was 
69.2 years (range 18-91 years). The breakdown of 
CLP locations were: 24% head, 32% body, 13% 
uncinate, 12% tail, and 19% involving multiple 
areas. The indications for the procedure varied 
from symptomatic to incidentally discovered 
lesions.  Diagnoses were classified as 
unsatisfactory, benign nonmucinous, benign 
mucinous, and suspicious/malignant. RedPath
criteria for mucinous lesions included k-ras-2 gene 
point mutation, high DNA quantity (optical density 
ratio >10) / DNA quality, or loss of heterozygosity
(LOH) in ≥2 genomic loci; criteria for malignancy 
included k-ras-2 gene mutation, high amplitude 
(>75%), or ≥2 genomic loci with LOH, high 
amplitude (>75%).
Concordant diagnoses were seen in 56% (35/63) of 
cases. In 10 cases (16%), there was disagreement 
between cytology and molecular. Elevated CEA 
levels (>192 ng/ml) were seen in 25% of cases, each 
diagnosed as a mucinous lesion with molecular 
analysis. In 4 cases (6%) CEA was elevated when 
cytology was unsatisfactory, each diagnosed as 
benign mucinous cyst with molecular.  Molecular 
testing provided a diagnosis in 20 cases (32%) when 
either cytology was unsatisfactory, or CEA not 
elevated (<192 ng/ml).
The results of our study demonstrate the addition 
of molecular analysis significantly increases the 
diagnostic yield of CLP ≤3 cm when used in conjunction 
with cytology and cyst fluid CEA levels. 
Our results showed poor agreement between CEA 
and molecular analysis, consistent with previous work 
with regard to correlating these diagnostic modalities. 
This finding was previously attributed to the 
requirement for lining cells to secrete CEA, while 
molecular analysis depends on these same lining cells 
to acquire specific mutations.(5)  
An example of the diagnostic sensitivity of molecular 
analysis is illustrated by a case in our study initially 
diagnosed as a benign mucinous lesion on cytology,
while molecular analysis diagnosed malignancy. In 
view of the molecular findings, a repeat FNA was 
performed, and cytology now interpreted the lesion as 
suspicious for adenocarcinoma. A subsequent surgical 
resection revealed adenocarcinoma arising in 
association with an IPMN. In this case appropriate 
clinical management occurred as a direct result of 
molecular analysis.
In summary, we have presented data demonstrating 
molecular analysis adds to the diagnostic sensitivity of 
pancreatic FNA. This benefit becomes even more 
pronounced in scant specimens when cytology may be 
unsatisfactory and CEA unreliable.
Analysis of McNemar’s test demonstrated a 
statistically significant benefit (p=0.001) with regard 
to the ability of molecular analysis to aid in providing 
a diagnosis when compared to cytology. This value 
was also significant when applying the criteria of 
elevated CEA to identify a mucinous CLP (p=0.01).
Table I: Ability to Render a Diagnosis
Cytology 44 / 63 (70%)
Elevated  CEA 16 / 63 (25%)
Molecular analysis 61 / 63 (97%)
Cytology unsatisfactory,
Molecular diagnostic 17 / 63 (27%)
CEA not elevated, however
Molecular diagnoses mucinous lesion 8 / 63 (13%)
Table II: Comparison of Mucinous and Nonmucinous
Pancreatic Cysts by Molecular Diagnosis
Diagnostic Test(s) % of Cases with Diagnosis
K-ras mutation 0 / 63 (0%) 13 / 63 (21%)1
Allelic loss 4 / 63 (6%) 7 / 63 (11%)
K-ras mutation and 
allelic loss 0 / 63 (0%) 4 / 63 (6%)2
CEA (ng/ml) median 6.1 403
Nonmucinous / Benign Mucinous / Neoplastic
1 Two cases showed high amplitude (>75%) K-ras mutations at codon 12; 11 cases showed low 
amplitude (<75%) K-ras mutations at codon 12 
2  All cases showed low amplitude allelic loss (<75%); 2 cases showed allelic loss at 1 genomic loci, 
1 case showed allelic loss at 2 genomic loci, and 1 case showed allelic loss at 3 genomic loci
Figure 1: Sample RedPath report illustrating the genetic tests 
performed on pancreatic cysts. In this case the presence of a KRAS 
mutation in combination with low DNA quality/quantity, as well as 
no allelic loss, was diagnosed as an indolent mucinous lesion.
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